drugset / Trial / NCT04221217
Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of MND-2119 at a dose of 2g/day or 4g/day for 52 weeks in patients with hypertriglyceridemia.
Timeline
- Start
- 2020-02-14
- Primary completion
- 2021-07-14
- Completion
- 2021-07-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eicosapentaenoic acid | Small molecule | 2 g | Oral |
| Subject | Eicosapentaenoic acid | Small molecule | 4 g | Oral |